UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)

Gynecologic oncology, 2018-01, Vol.148 (1), p.36-41

2018

Volltextzugriff (PDF)

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

International journal of gynecological cancer, 2022-06, Vol.32 (6), p.761-768

2022

Volltextzugriff (PDF)

Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer

Gynecologic oncology, 2022-08, Vol.166 (2), p.254-262

2022

Volltextzugriff (PDF)

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study

The oncologist (Dayton, Ohio), 2017-09, Vol.22 (9), p.1117-1124

2017

Volltextzugriff (PDF)

Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice

Patient related outcome measures, 2023-05, Vol.14, p.111-126

2023

Volltextzugriff (PDF)

Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-Analysis

JCO precision oncology, 2017-11 (1), p.1-12

2017

Volltextzugriff (PDF)

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy

Annals of oncology, 2017-08, Vol.28 (8), p.1849-1855

2017

Volltextzugriff (PDF)

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS284-TPS284

2022

Volltextzugriff (PDF)

Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study

Obstetrical & gynecological survey, 2022-09, Vol.77 (9), p.531-533

2022

Volltextzugriff (PDF)

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS5077-TPS5077

2015

Volltextzugriff (PDF)

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS5078-TPS5078

2015

Volltextzugriff (PDF)

Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5547-5547

2015

Volltextzugriff (PDF)

Convenors' Welcome

Asia-Pacific journal of clinical oncology, 2021-08, Vol.17 (S4), p.6-6

2021

Volltextzugriff (PDF)

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer

Cochrane database of systematic reviews, 2019-10, Vol.10 (10), p.CD012160-CD012160

2019

Volltextzugriff (PDF)

Adherence Outcomes and Risk Factors Predicting Nonadherence to Active Surveillance in Patients With Stage 1 Testicular Germ Cell Tumors

Clinical genitourinary cancer, 2024-08, Vol.22 (4), p.102116, Article 102116

2024

Volltextzugriff (PDF)

Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer

Gynecologic oncology, 2024-06, Vol.185, p.128-137

2024

Volltextzugriff (PDF)

UNICAB: Cabozantinib in locally advanced or metastatic non‐clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.428-428

2024

Volltextzugriff (PDF)

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14576-e14576

2019

Volltextzugriff (PDF)

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.328-328

2024

Volltextzugriff (PDF)

DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS396-TPS396

2023

Volltextzugriff (PDF)

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma

BJU international, 2024-02, Vol.133 (S3), p.57-67

2024

Volltextzugriff (PDF)

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5103-TPS5103

2022

Volltextzugriff (PDF)

Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4537-4537

2022

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)
Tagungsberichte
(4)

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Oncology
(12)
Medicin Och Hälsovetenskap
(9)
Humans
(5)
Obstetrics & Gynecology
(5)
Female
(4)
Quality Of Life
(4)
Middle Aged
(3)
Neoplasm Staging
(3)
Prognosis
(3)
Adult
(2)
Aged
(2)
Aged, 80 And Over
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Cancer
(2)
Drug Resistance, Neoplasm
(2)
General & Internal Medicine
(2)
Male
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study

Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice

Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-Analysis

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

Symptom Burden and Quality of Life With Chemotherapy for Recurrent Ovarian Cancer: The Gynecologic Cancer InterGroup-Symptom Benefit Study

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304)

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303)

Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy

Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS)

Convenors' Welcome

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer

Adherence Outcomes and Risk Factors Predicting Nonadherence to Active Surveillance in Patients With Stage 1 Testicular Germ Cell Tumors

Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer

UNICAB: Cabozantinib in locally advanced or metastatic non‐clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802)

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa)

DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma

Aktive Filter

Suchergebnisse filtern